Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LA-857
- Development stage
- Preclinical
- Lead developer
- Allero Therapeutics
- Modality
- Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
LA-857 is a preclinical allergen immunotherapy candidate from Allero Therapeutics for food allergies and pollen allergies. It uses the company's Sequential Oral Mucosal Immunotherapy platform, delivering allergen antigens together with Toll-like receptor-binding proteins through a mouth patch to the oral mucosa. The intended mechanism is induction of allergen-specific immune tolerance; the individual allergen antigens and the specific Toll-like receptor-binding proteins have not been publicly disclosed.
Beyond the preview
Go deeper on LA-857.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LA-857.